Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Up 6.9% - Here's Why

Key Points

• Regeneron Pharmaceuticals' stock price increased by 6.9%, closing at $600.85, after trading as high as $593.84 during the day.
• Analysts have a Moderate Buy consensus rating for Regeneron, with target prices ranging from $650 to $817.67.
• The company reported a quarterly earnings per share of $12.89, significantly exceeding the expected $8.43 and marking a revenue growth of 3.6% year-over-year.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report)'s stock price traded up 6.9% during trading on Wednesday . The stock traded as high as $593.84 and last traded at $600.85. 209,708 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 1,095,438 shares. The stock had previously closed at $562.27.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent analyst reports. Truist Financial cut their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Citigroup reaffirmed a "buy" rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Finally, JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday, June 9th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Stock Up 7.9%

The firm has a market capitalization of $64.33 billion, a price-to-earnings ratio of 15.29, a price-to-earnings-growth ratio of 1.79 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The business's 50 day moving average is $570.12 and its 200-day moving average is $568.72.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same period in the prior year, the company earned $11.56 earnings per share. The business's quarterly revenue was up 3.6% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently bought and sold shares of REGN. Marietta Wealth Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 30.2% during the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock worth $6,836,000 after purchasing an additional 2,501 shares during the period. Sepio Capital LP grew its position in Regeneron Pharmaceuticals by 33.1% during the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock worth $2,150,000 after buying an additional 842 shares in the last quarter. Founders Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 7.0% during the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company's stock valued at $4,344,000 after acquiring an additional 538 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after acquiring an additional 955 shares in the last quarter. Finally, KBC Group NV lifted its position in shares of Regeneron Pharmaceuticals by 9.4% in the 1st quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock worth $94,779,000 after acquiring an additional 12,793 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.